Latest period
$180.60M
YoY change
+49.5%
5Y CAGR
+67.8%
Peak year (2025)
$118.39M
Latest annual
$118.39M
Stock-Based Compensation history chart for Revolution Medicines (RVMD) from 2017 to 2025
Latest: $118.39M
Stock-Based Compensation growth chart for Revolution Medicines (RVMD) from 2017 to 2025
Latest: +49.5%
Stock-Based Compensation history table for Revolution Medicines (RVMD) from 2017 to 2025
| 2025 | $118.39M | +49.5% | +$39.19M | ||
| 2024 | $79.20M | +28.2% | +$17.43M | ||
| 2023 | $61.77M | +98.0% | +$30.58M | ||
| 2022 | $31.20M | +50.5% | +$10.47M | ||
| 2021 | $20.72M | +133.2% | +$11.84M | ||
| 2020 | $8.89M | +181.1% | +$5.72M | ||
| 2019 | $3.16M | +269.7% | +$2.31M | ||
| 2018 | $855.00K | +506.4% | +$714.00K | ||
| 2017 | $141.00K | — | — |
- 2025$118.39M+49.5%
- 2024$79.20M+28.2%
- 2023$61.77M+98.0%
- 2022$31.20M+50.5%
- 2021$20.72M+133.2%
- 2020$8.89M+181.1%
- 2019$3.16M+269.7%
- 2018$855.00K+506.4%
- 2017$141.00K—
Stock-Based Compensation values are taken from Revolution Medicines's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Stock-Based Compensation at Revolution Medicines (RVMD)
Stock-Based Compensation for Revolution Medicines (RVMD): headline value $180.60M · YoY +49.5%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
In 2025, Revolution Medicines (RVMD) stock-based compensation totalled $118.39M – surged 49.5% year-over-year.
Looking at the 2020–2025 (5 years) stretch, Revolution Medicines stock-based compensation compounded at +67.8% per year, with mixed annual results across the window.
The highest annual stock-based compensation of $118.39M was reported in 2025. The lowest in the available history was $141.00K in 2017.
Revolution Medicines Stock-Based Compensation by Year
Revolution Medicines Stock-Based Compensation 2025: $118.39M
Revolution Medicines posted stock-based compensation of $118.39M in 2025, surged 49.5% from 2024. This figure represents the highest annual value in the available history.
Revolution Medicines Stock-Based Compensation 2024: $79.20M
In 2024, Revolution Medicines reported stock-based compensation of $79.20M, grew 28.2% from 2023.
Revolution Medicines Stock-Based Compensation 2023: $61.77M
Revolution Medicines stock-based compensation in 2023 was $61.77M, surged 98.0% from 2022.
Revolution Medicines Stock-Based Compensation 2022: $31.20M
2022's stock-based compensation for Revolution Medicines came in at $31.20M, surged 50.5% from 2021.
Revolution Medicines Stock-Based Compensation 2021: $20.72M
Revolution Medicines stock-based compensation in 2021 was $20.72M.
See more financial history for Revolution Medicines (RVMD).
Sector peers by Stock-Based Compensation
Healthcare peers of Revolution Medicines (RVMD), ranked by their latest stock-based compensation
| $1.35B | |
| $971.00M | |
| $955.00M | |
| $626.00M | |
| $0.00 | |
| $0.00 | |
| $0.00 | |
| $0.00 |
- $1.35B
- $971.00M
- $955.00M
- $626.00M
- $0.00
- $0.00
- $0.00
- $0.00
Frequently asked questions
Revolution Medicines (RVMD) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation